PDGFRA Antibody for Soft Tissue Sarcoma

Lillian R. Klug, Michael Heinrich

    Research output: Contribution to journalShort survey

    5 Scopus citations

    Abstract

    Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin chemotherapy significantly improved overall survival, leading to FDA approval.

    Original languageEnglish (US)
    Pages (from-to)555
    Number of pages1
    JournalCell
    Volume168
    Issue number4
    DOIs
    StatePublished - Feb 9 2017

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)

    Fingerprint Dive into the research topics of 'PDGFRA Antibody for Soft Tissue Sarcoma'. Together they form a unique fingerprint.

  • Cite this